MESOMARK™: A Potential Test for Malignant Pleural Mesothelioma

Beyer, Heather L.; Geschwindt, Ryan; Glover, Curtis L.; Trần, Lý Thị; Hellström, Ingegerd; Hellstrom, Karl-Erik; Miller, Michael Craig; Verch, Thorsten; Allard, W. Jeffrey; Pass, Harvey I.; Sardesai, Niranjan Y.

doi:10.1373/clinchem.2006.079327

Cited by 127 publications

(139 citation statements)

References 15 publications

Supporting

Mentioning

123

Contrasting

Order By: Relevance

“…Higher clinical stages of mesothelioma (stages II and III-IV) are associated with higher SMRP concentrations 6,58,69,71 . Other data suggest that serum mesothelin levels increase as the tumor grows 53,70,71 . On the other hand, surgical tumor reduction is followed by a decrease in SMRP levels 6,35,68 .…”

Section: Discussionmentioning

confidence: 99%

“…But recent studies recommend that SMRP should not be used in the screening for mesothelioma in asbestosexposed persons 3,61 . Numerous studies have been performed to assess the utilization of mesothelin in the diagnosis of mesothelioma, reporting a sensitivity of 50-84% and specificity of 72-95% and statistically significantly higher SMRP levels in mesothelioma as compared with healthy exposed individuals or those with benign asbestos-induced conditions 30,31,35,55,[68][69][70][71][72] . Recent meta-analysis reported a sensitivity and specificity of SMRP for mesothelioma of 32-64% and 88-100%, respectively 73,74 .…”

Section: Discussionmentioning

confidence: 99%

“…Another finding in many studies was statistically significantly higher mesothelin levels in mesothelioma than in metastatic involvement of the pleura but also statistically significantly higher mesothelin concentrations in metastatic pleural disease compared with asbestos-exposed individuals (healthy and/or with benign disease) (ref. 37,63,65,70 ). Large differences in results between individual studies are probably due to different cut-off values used.…”

Section: Discussionmentioning

confidence: 99%

“…There have been studies measuring pleural SMRP, the absolute values of which tend to be higher than those of serum SMRP, showing similar sensitivity and specificity 6,37,58,75 . Most studies have shown higher SMRP levels in epithelioid mesothelioma than in other mesothelioma types, with an SMRP sensitivity of only 10% in sarcomatoid mesothelioma and 40% in the mixed type 30,36,37,53,[69][70][71]76,77 . Also in the presented group of subjects examined for pleural effusions of unknown etiology, the sensitivity, specificity, negative predictive value, accuracy and median of serum mesothelin were higher in epithelioid mesothelioma than in the group of all mesothelioma types 78 .…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Significance of serum mesothelin in an asbestos-exposed population in the Czech Republic

Jakubec¹,

Pelclová²,

Smolková³

et al. 2015

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub

View full text Add to dashboard Cite

Aims. Pleural mesothelioma is a highly aggressive and difficult-to-treat form of cancer induced by asbestos in 80-90% of cases. The population group most at risk of the condition are asbestos-exposed workers. Mesothelin or soluble mesothelin-related protein (SMRP) is studied as a potential marker of mesothelioma in the at-risk population. Methods. The study comprised 239 subjects with a mean duration of occupational exposure to asbestos of 19.9 years. In all of them, a complete medical history was taken, focused on exposure duration and a physical examination, a chest X-ray or other imaging investigations and a lung function test were performed. Their serum SMRP levels were measured and biopsy samples were taken to diagnose pleural disease. Based on the above examinations, the subjects were classified into subgroups and serum SMRP concentrations were statistically analyzed with respect to individual parameters. Results. In asbestos-exposed individuals, mesothelin levels were significantly higher in those with pathological X-ray findings than in those with normal X-ray results (0.78 ± 0.63 vs. 0.50 ± 0.35, P<0.0001). The group of patients with benign disease had statistically significantly higher mesothelin levels than those with normal X-ray findings (0.755 ± 0.543 vs. 0.50 ± 0.35, P<0.001). In the group with present malignant processes, mesothelin levels were higher than in individuals with benign disease (1.19 ± 0.89 vs. 0.76 ± 0.54, P=0.015). Only a weak correlation was found between mesothelin levels and asbestos exposure duration. There were relatively high sensitivity and high specificity (75% and 90.6%, respectively) of serum mesothelin for pleural mesothelioma. However, given the small number of mesothelioma cases in the group, the results cannot be considered as statistically significant. Conclusions. In persons followed up for asbestos exposure, increased mesothelin levels signalize pathological processes in the chest and correlate with severity of the disease. The study suggests that mesothelin cannot be considered a reliable marker for the early stage of malignant degeneration of pleural disease but only an additional criterion for examination of the followed-up individuals.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Significance of serum mesothelin in an asbestos-exposed population in the Czech Republic

Jakubec¹,

Pelclová²,

Smolková³

et al. 2015

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub

View full text Add to dashboard Cite

show abstract

“…The data available for the second assay is limited and it is difficult to say if this assay is better than the Mesomark™ kit which has been used by the majority of investigators and showed a very good reproducibility and precision with little constraints concerning sample storage or interference with other substances [47][48][49]. A head to head comparison of the two kits would be useful but is presently unavailable.…”

Section: Mesothelinmentioning

confidence: 99%

Clinical utility of diagnostic markers for malignant pleural mesothelioma

Grigoriu

Grigoriu²,

Chahine

et al. 2016

Monaldi Arch Chest Dis

View full text Add to dashboard Cite

Malignant mesothelioma has a very dismal prognosis with very few patients surviving one year after diagnosis. Early multimodal treatment, however, is expected to improve the outcome. Today, there is a strong need to have disease markers which could be used for screening, diagnosing, and/or monitoring tumour response to treatment. Old markers such as hyaluronic acid, various cytokeratin fragments (CYFRA 21.1, TPA) and other cancer antigens (CA 15.3, CA 125 or CA 19.9 or CEA) are not sensitive or specific enough and cannot be used in practice. More recently new molecules, such as soluble mesothelin and osteopontin, have been proposed for diagnostic purposes. Soluble mesothelin has a good specificity but has a suboptimal sensitivity being negative in all sarcomatoid and in up to one half of epithelioid mesothelioma. On the contrary osteopontin has an inadequate specificity. Combining different markers together does not lead to an improvement in diagnostic accuracy. Neither marker can be used for screening purposes, the main limitation being the very low incidence of the disease in the at-risk, asbestos exposed population. Mesothelin is also a promising marker for monitoring response to treatment but published data is still insufficient to make recommendations. There is still a strong need for research is this area both in order to discover new markers as well as to correct the positioning of each existing molecule (alone or in combination) is the evaluation of the patients with a mesothelioma.

show abstract

Immunotherapy targeting mesothelin in acute myeloid leukemia

Wang

Gong

2022

Journal of Leukocyte Biology

View full text Add to dashboard Cite

Mesothelin (MSLN) is an emerging target that exists in soluble and membrane‐associated forms. It is usually used for the diagnosis and treatment of MSLN‐positive solid tumors. Interestingly, recent studies have shown that MSLN is highly expressed in 36% of acute myeloid leukemia (AML) patients and barely expressed in normal hematopoietic cells, which makes MSLN a promising target for the treatment of AML. It has been shown that MSLN is detectable as a diagnostic marker in its soluble form. Although the mechanism of action is unclear, MSLN remains a promising target for immunotherapy. Most MSLN research has been conducted in solid tumors, and less research has been conducted in hematopoietic tumors. Increasing research on MSLN is underway in AML, a hematopoietic neoplasm. For example, MSLN is related to extramedullary disease, minimal residual disease, and relapse in AML patients. Decreasing the expression of MSLN reduces the severity of the disease course. This information suggests that MSLN may be an ideal target for the treatment of many AML‐related diseases to improve the prognosis and survival rate. At present, there are a few immunotherapies targeting MSLN in AML in preclinical and clinical trials, such as antibody‒drug conjugates, bispecific T‐cell engagers, and chimeric antigen receptor‐T cells, which opens new room for the treatment of MSLN‐related AML.

show abstract

MESOMARK™: A Potential Test for Malignant Pleural Mesothelioma

Cited by 127 publications

References 15 publications

Significance of serum mesothelin in an asbestos-exposed population in the Czech Republic

Significance of serum mesothelin in an asbestos-exposed population in the Czech Republic

Clinical utility of diagnostic markers for malignant pleural mesothelioma

Immunotherapy targeting mesothelin in acute myeloid leukemia

Contact Info

Product

Resources

About